Tanvex BioPharma Inc - Asset Resilience Ratio
Tanvex BioPharma Inc (6541) has an Asset Resilience Ratio of 3.85% as of June 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2018)
This chart shows how Tanvex BioPharma Inc's Asset Resilience Ratio has changed over time. Check 6541 capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Tanvex BioPharma Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Tanvex BioPharma Inc (6541) total market value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$130.28 Million | 3.85% |
| Total Liquid Assets | NT$130.28 Million | 3.85% |
Asset Resilience Insights
- Limited Liquidity: Tanvex BioPharma Inc maintains only 3.85% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Tanvex BioPharma Inc Industry Peers by Asset Resilience Ratio
Compare Tanvex BioPharma Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
ALTEOGEN Inc
KQ:196170 |
Biotechnology | 55.57% |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE |
Biotechnology | 47.01% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 34.94% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Galapagos N.V.
AS:GLPG |
Biotechnology | 86.45% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
Annual Asset Resilience Ratio for Tanvex BioPharma Inc (2016–2018)
The table below shows the annual Asset Resilience Ratio data for Tanvex BioPharma Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2018-12-31 | 42.35% | NT$1.90 Billion ≈ $59.75 Million |
NT$4.48 Billion ≈ $141.11 Million |
+15.84pp |
| 2017-12-31 | 26.50% | NT$1.05 Billion ≈ $33.18 Million |
NT$3.97 Billion ≈ $125.17 Million |
-15.17pp |
| 2016-12-31 | 41.67% | NT$1.61 Billion ≈ $50.84 Million |
NT$3.87 Billion ≈ $122.00 Million |
-- |
About Tanvex BioPharma Inc
Tanvex BioPharma, Inc., a pharmaceutical company, engages in the research, development, manufacture, and sale of biosimilar products in Taiwan and the United States. The company focuses on delivering biopharmaceuticals with biosimilars targeting neutropenia, breast cancer, metastatic colorectal cancer, and psoriasis. It also engages in contract development and manufacturing of biological medicine… Read more